Quarterly report · Q2

Period2023-04-01 → 2023-09-30
Filed2023-11-07
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 60
MetricValuePeriodScopeSource row
Revenue¥1.19T2023-04-01 → 2023-09-30Cons.Revenue IFRS
Revenue¥623.7bn2023-07-01 → 2023-09-30dCons.Revenue IFRS
Revenue¥2.90T2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥1.53T2022-04-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥754.4bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Operating income−¥133.7bn2023-04-01 → 2023-09-30Cons.Operating profit loss IFRS
Operating income−¥61.9bn2023-07-01 → 2023-09-30dCons.Operating profit loss IFRS
Operating income¥60.6bn2022-04-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income−¥5.7bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Profit before tax−¥103.8bn2023-04-01 → 2023-09-30Cons.Profit loss before tax IFRS
Profit before tax−¥53.9bn2023-07-01 → 2023-09-30dCons.Profit loss before tax IFRS
Profit before tax¥231m2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥126.8bn2022-04-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥13.1bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Net income (owners)−¥76.3bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥43.2bn2023-07-01 → 2023-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥7.0bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥81.1bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥11.1bn2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income−¥107.0bn2023-04-01 → 2023-09-30Cons.Profit loss IFRS
Net income−¥55.9bn2023-07-01 → 2023-09-30dCons.Profit loss IFRS
Net income−¥46.9bn2022-04-01 → 2023-03-31Cons.Profit loss IFRS (5-year summary)
Net income¥73.1bn2022-04-01 → 2022-09-30Cons.Profit loss IFRS
Net income−¥12.0bn2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Total assets¥4.38Tat 2023-09-30Cons.Assets IFRS
Total assets¥4.17Tat 2023-03-31Cons.Assets IFRS
Total assets¥4.68Tat 2022-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥2.83Tat 2023-09-30Cons.Liabilities IFRS
Total liabilities¥2.68Tat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥1.55Tat 2023-09-30Cons.Equity IFRS
Net assets / equity¥1.49Tat 2023-03-31Cons.Equity IFRS
Net assets / equity¥1.89Tat 2022-09-30Cons.Equity IFRS
Net assets / equity¥1.70Tat 2022-03-31dCons.Equity IFRS
Equity (owners)¥1.22Tat 2023-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.17Tat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.38Tat 2022-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥277.7bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥305.8bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥486.0bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥365.4bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow−¥115.3bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥111.6bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥83.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥79.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥19.4bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow¥15.6bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥140.2bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥178.5bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥24.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-46.692023-04-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥-26.412023-07-01 → 2023-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥4.272022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥49.582022-04-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥6.772022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥4.272022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥49.572022-04-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥6.772022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio27.9%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio28.1%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio29.5%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 123
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-09-30¥76.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-07-01 → 2023-09-30¥38.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-09-30¥34.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-07-01 → 2023-09-30¥17.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-09-30¥41.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-07-01 → 2023-09-30¥21.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-09-30¥4.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-07-01 → 2023-09-30¥1.9bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥56.0bn
Reconciling Itemsreconcilingrevenue2023-07-01 → 2023-09-30−¥28.2bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥56.0bn
Reconciling Itemsreconcilingrevenue intersegment2023-07-01 → 2023-09-30−¥28.2bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥7.9bn
Reconciling Itemsreconcilingsegment profit2023-07-01 → 2023-09-30−¥3.5bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue2023-04-01 → 2023-09-30¥159.8bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue2023-07-01 → 2023-09-30¥80.9bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue external2023-04-01 → 2023-09-30¥149.9bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue external2023-07-01 → 2023-09-30¥76.5bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥9.9bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue intersegment2023-07-01 → 2023-09-30¥4.4bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentsegment profit2023-04-01 → 2023-09-30¥6.5bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentsegment profit2023-07-01 → 2023-09-30¥3.5bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue2023-04-01 → 2023-09-30¥393.1bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue2023-07-01 → 2023-09-30¥199.4bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue external2023-04-01 → 2023-09-30¥390.3bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue external2023-07-01 → 2023-09-30¥197.9bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥2.8bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue intersegment2023-07-01 → 2023-09-30¥1.4bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentsegment profit2023-04-01 → 2023-09-30−¥44.4bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentsegment profit2023-07-01 → 2023-09-30−¥23.4bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue2023-04-01 → 2023-09-30¥243.1bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue2023-07-01 → 2023-09-30¥139.6bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue external2023-04-01 → 2023-09-30¥241.2bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue external2023-07-01 → 2023-09-30¥138.5bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥1.8bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue intersegment2023-07-01 → 2023-09-30¥1.1bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentsegment profit2023-04-01 → 2023-09-30−¥7.6bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentsegment profit2023-07-01 → 2023-09-30−¥509m
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue2023-04-01 → 2023-09-30¥203.9bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue2023-07-01 → 2023-09-30¥109.3bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue external2023-04-01 → 2023-09-30¥203.7bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue external2023-07-01 → 2023-09-30¥109.2bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥220m
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue intersegment2023-07-01 → 2023-09-30¥110m
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentsegment profit2023-04-01 → 2023-09-30¥17.8bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentsegment profit2023-07-01 → 2023-09-30¥11.2bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue2023-04-01 → 2023-09-30¥166.9bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue2023-07-01 → 2023-09-30¥83.9bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue external2023-04-01 → 2023-09-30¥166.9bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue external2023-07-01 → 2023-09-30¥83.9bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥1m
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentsegment profit2023-04-01 → 2023-09-30−¥65.5bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentsegment profit2023-07-01 → 2023-09-30−¥32.2bn
—segment totalrevenue2023-04-01 → 2023-09-30¥1.17T
—segment totalrevenue2023-07-01 → 2023-09-30¥613.2bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥1.15T
—segment totalrevenue external2023-07-01 → 2023-09-30¥606.1bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥14.7bn
—segment totalrevenue intersegment2023-07-01 → 2023-09-30¥7.0bn
—segment totalsegment profit2023-04-01 → 2023-09-30−¥93.1bn
—segment totalsegment profit2023-07-01 → 2023-09-30−¥41.5bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-09-30¥79.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-07-01 → 2022-09-30¥47.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-09-30¥37.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-07-01 → 2022-09-30¥23.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-09-30¥42.1bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-07-01 → 2022-09-30¥24.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-09-30¥2.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-07-01 → 2022-09-30−¥708m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥57.6bn
Reconciling Itemsreconcilingrevenue2022-07-01 → 2022-09-30−¥32.7bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥57.6bn
Reconciling Itemsreconcilingrevenue intersegment2022-07-01 → 2022-09-30−¥32.7bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥11.6bn
Reconciling Itemsreconcilingsegment profit2022-07-01 → 2022-09-30−¥4.1bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue2022-04-01 → 2022-09-30¥183.7bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue2022-07-01 → 2022-09-30¥92.4bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue external2022-04-01 → 2022-09-30¥173.5bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue external2022-07-01 → 2022-09-30¥87.1bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥10.1bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥5.3bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentsegment profit2022-04-01 → 2022-09-30¥13.4bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentsegment profit2022-07-01 → 2022-09-30¥6.8bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue2022-04-01 → 2022-09-30¥470.4bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue2022-07-01 → 2022-09-30¥230.3bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue external2022-04-01 → 2022-09-30¥467.3bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue external2022-07-01 → 2022-09-30¥228.7bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3.1bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥1.6bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentsegment profit2022-04-01 → 2022-09-30¥23.3bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentsegment profit2022-07-01 → 2022-09-30¥13.3bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue2022-04-01 → 2022-09-30¥295.9bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue2022-07-01 → 2022-09-30¥142.4bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue external2022-04-01 → 2022-09-30¥293.9bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue external2022-07-01 → 2022-09-30¥141.3bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥2.0bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥1.1bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentsegment profit2022-04-01 → 2022-09-30¥36.3bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentsegment profit2022-07-01 → 2022-09-30¥14.4bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue2022-04-01 → 2022-09-30¥222.4bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue2022-07-01 → 2022-09-30¥107.7bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue external2022-04-01 → 2022-09-30¥222.2bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue external2022-07-01 → 2022-09-30¥107.5bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥234m
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥118m
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentsegment profit2022-04-01 → 2022-09-30¥26.4bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentsegment profit2022-07-01 → 2022-09-30¥10.7bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue2022-04-01 → 2022-09-30¥334.5bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue2022-07-01 → 2022-09-30¥166.7bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue external2022-04-01 → 2022-09-30¥334.4bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue external2022-07-01 → 2022-09-30¥166.7bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥7m
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥1m
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentsegment profit2022-04-01 → 2022-09-30¥25.2bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentsegment profit2022-07-01 → 2022-09-30¥11.1bn
—segment totalrevenue2022-04-01 → 2022-09-30¥1.51T
—segment totalrevenue2022-07-01 → 2022-09-30¥739.5bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥1.49T
—segment totalrevenue external2022-07-01 → 2022-09-30¥731.4bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥15.5bn
—segment totalrevenue intersegment2022-07-01 → 2022-09-30¥8.1bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥124.7bn
—segment totalsegment profit2022-07-01 → 2022-09-30¥56.3bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,060
ItemContextValueUnit
Equity attributable to owners of parent IFRSPrior1YearInstant1171192000000JPY
Equity attributable to owners of parent IFRSCurrentQuarterInstant1223990000000JPY
Non controlling interests IFRSPrior1YearInstant317997000000JPY
Non controlling interests IFRSCurrentQuarterInstant325187000000JPY
Equity IFRSPrior1YearInstant1489189000000JPY
Equity IFRSCurrentQuarterInstant1549177000000JPY
Liabilities and equity IFRSPrior1YearInstant4165503000000JPY
Liabilities and equity IFRSCurrentQuarterInstant4384121000000JPY
Revenue IFRSPrior1YTDDuration1528563000000JPY
Revenue IFRSCurrentYTDDuration1186875000000JPY
Cost of sales IFRSPrior1YTDDuration1051430000000JPY
Cost of sales IFRSCurrentYTDDuration930586000000JPY
Gross profit IFRSPrior1YTDDuration477133000000JPY
Gross profit IFRSCurrentYTDDuration256289000000JPY
Selling general and administrative expenses IFRSPrior1YTDDuration447258000000JPY
Selling general and administrative expenses IFRSCurrentYTDDuration349216000000JPY
Other operating income IFRSPrior1YTDDuration12881000000JPY
Other operating income IFRSCurrentYTDDuration12411000000JPY
Other operating expenses IFRSPrior1YTDDuration12069000000JPY
Other operating expenses IFRSCurrentYTDDuration26255000000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration29880000000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentYTDDuration-26908000000JPY
Operating profit loss IFRSPrior1YTDDuration60567000000JPY
Operating profit loss IFRSCurrentYTDDuration-133679000000JPY
Finance income IFRSPrior1YTDDuration91208000000JPY
Finance income IFRSCurrentYTDDuration56548000000JPY
Finance costs IFRSPrior1YTDDuration24997000000JPY
Finance costs IFRSCurrentYTDDuration26665000000JPY
Profit loss before tax IFRSPrior1YTDDuration126778000000JPY
Profit loss before tax IFRSCurrentYTDDuration-103796000000JPY
Income tax expense IFRSPrior1YTDDuration53716000000JPY
Income tax expense IFRSCurrentYTDDuration3252000000JPY
Profit loss IFRSPrior1YTDDuration73062000000JPY
Profit loss IFRSCurrentYTDDuration-107048000000JPY
Profit loss attributable to owners of parent IFRSPrior1YTDDuration81063000000JPY
Profit loss attributable to owners of parent IFRSCurrentYTDDuration-76346000000JPY
Profit loss attributable to non controlling interests IFRSPrior1YTDDuration-8001000000JPY
Profit loss attributable to non controlling interests IFRSCurrentYTDDuration-30702000000JPY
Profit loss IFRSPrior1YTDDuration73062000000JPY
Profit loss IFRSCurrentYTDDuration-107048000000JPY
Basic earnings loss per share IFRSPrior1YTDDuration49.58
Basic earnings loss per share IFRSCurrentYTDDuration-46.69
Diluted earnings loss per share IFRSPrior1YTDDuration49.57
Diluted earnings loss per share IFRSCurrentYTDDuration-
Revenue IFRSPrior1QuarterDuration754429000000JPY
Revenue IFRSCurrentQuarterDuration623732000000JPY
Cost of sales IFRSPrior1QuarterDuration523085000000JPY
Cost of sales IFRSCurrentQuarterDuration496575000000JPY
Gross profit IFRSPrior1QuarterDuration231344000000JPY
Gross profit IFRSCurrentQuarterDuration127157000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2023-07-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass